Research ExplorerPublicationsReceptor activator of nuclear factor kappaB ligand plays a n...

Receptor activator of nuclear factor kappaB ligand plays a nonredundant role in doxorubicin-induced apoptosis

Standard

Receptor activator of nuclear factor kappaB ligand plays a nonredundant role in doxorubicin-induced apoptosis. / Müller, Ingo; Pfister, Stefan M; Grohs, Ulrike; Zweigner, Janine; Handgretinger, Rupert; Niethammer, Dietrich; Bruchelt, Gernot.

In: CANCER RES, Vol. 63, No. 8, 15.04.2003, p. 1772-5.

Research output: SCORING: Contribution to journal › SCORING: Journal article › Research › peer-review

Harvard

Müller, I, Pfister, SM, Grohs, U, Zweigner, J, Handgretinger, R, Niethammer, D & Bruchelt, G 2003, 'Receptor activator of nuclear factor kappaB ligand plays a nonredundant role in doxorubicin-induced apoptosis', CANCER RES, vol. 63, no. 8, pp. 1772-5.

APA

Müller, I., Pfister, S. M., Grohs, U., Zweigner, J., Handgretinger, R., Niethammer, D., & Bruchelt, G. (2003). Receptor activator of nuclear factor kappaB ligand plays a nonredundant role in doxorubicin-induced apoptosis. CANCER RES, 63(8), 1772-5.

Vancouver

Müller I, Pfister SM, Grohs U, Zweigner J, Handgretinger R, Niethammer D et al. Receptor activator of nuclear factor kappaB ligand plays a nonredundant role in doxorubicin-induced apoptosis. CANCER RES. 2003 Apr 15;63(8):1772-5.

Bibtex

@article{b004ceb262c848948b7ce03154543187,
title = "Receptor activator of nuclear factor kappaB ligand plays a nonredundant role in doxorubicin-induced apoptosis",
abstract = "Doxorubicin induces apoptosis in a variety of cells. We investigated the expression and function of various tumor necrosis factor (TNF)alpha-homologues and their receptors. CEM cells did not differentially express any one of the TNFalpha-homologous receptors investigated nor TNF-related apoptosis-inducing ligand or TNF-related weakly apoptosis-inducing ligand (TWEAK) in the presence of doxorubicin. In addition to CD95 ligand, however, receptor activator of nuclear factor kappaB ligand (RANKL) was strongly up-regulated. Doxorubicin-induced apoptosis was greatly suppressed in the presence of either neutralizing antibody or RANK-Fc fusion protein. Moreover, neutralizing RANKL also prevented cytochrome c release from mitochondria. RANKL alone was unable to induce significant levels of apoptosis in CEM cells. However, doxorubicin-induced apoptosis was increased >2-fold when exogenous RANKL was added. Therefore, RANKL is necessary but not sufficient to account for early doxorubicin-induced apoptosis in CEM cells. This finding suggests improved chemotherapeutic efficiency of the anthracyclin against susceptible malignant cells in the presence with RANKL.",
keywords = "Antibiotics, Antineoplastic, Apoptosis, Carrier Proteins, Cell Line, Cytochrome c Group, Doxorubicin, Drug Synergism, Humans, Membrane Glycoproteins, Mitochondria, NF-kappa B, RANK Ligand, Receptor Activator of Nuclear Factor-kappa B, Staurosporine, T-Lymphocytes, Tumor Necrosis Factor-alpha",
author = "Ingo M{\"u}ller and Pfister, {Stefan M} and Ulrike Grohs and Janine Zweigner and Rupert Handgretinger and Dietrich Niethammer and Gernot Bruchelt",
year = "2003",
month = apr,
day = "15",
language = "English",
volume = "63",
pages = "1772--5",
journal = "CANCER RES",
issn = "0008-5472",
publisher = "American Association for Cancer Research Inc.",
number = "8",

}

RIS

TY - JOUR

T1 - Receptor activator of nuclear factor kappaB ligand plays a nonredundant role in doxorubicin-induced apoptosis

AU - Müller, Ingo

AU - Pfister, Stefan M

AU - Grohs, Ulrike

AU - Zweigner, Janine

AU - Handgretinger, Rupert

AU - Niethammer, Dietrich

AU - Bruchelt, Gernot

PY - 2003/4/15

Y1 - 2003/4/15

N2 - Doxorubicin induces apoptosis in a variety of cells. We investigated the expression and function of various tumor necrosis factor (TNF)alpha-homologues and their receptors. CEM cells did not differentially express any one of the TNFalpha-homologous receptors investigated nor TNF-related apoptosis-inducing ligand or TNF-related weakly apoptosis-inducing ligand (TWEAK) in the presence of doxorubicin. In addition to CD95 ligand, however, receptor activator of nuclear factor kappaB ligand (RANKL) was strongly up-regulated. Doxorubicin-induced apoptosis was greatly suppressed in the presence of either neutralizing antibody or RANK-Fc fusion protein. Moreover, neutralizing RANKL also prevented cytochrome c release from mitochondria. RANKL alone was unable to induce significant levels of apoptosis in CEM cells. However, doxorubicin-induced apoptosis was increased >2-fold when exogenous RANKL was added. Therefore, RANKL is necessary but not sufficient to account for early doxorubicin-induced apoptosis in CEM cells. This finding suggests improved chemotherapeutic efficiency of the anthracyclin against susceptible malignant cells in the presence with RANKL.

AB - Doxorubicin induces apoptosis in a variety of cells. We investigated the expression and function of various tumor necrosis factor (TNF)alpha-homologues and their receptors. CEM cells did not differentially express any one of the TNFalpha-homologous receptors investigated nor TNF-related apoptosis-inducing ligand or TNF-related weakly apoptosis-inducing ligand (TWEAK) in the presence of doxorubicin. In addition to CD95 ligand, however, receptor activator of nuclear factor kappaB ligand (RANKL) was strongly up-regulated. Doxorubicin-induced apoptosis was greatly suppressed in the presence of either neutralizing antibody or RANK-Fc fusion protein. Moreover, neutralizing RANKL also prevented cytochrome c release from mitochondria. RANKL alone was unable to induce significant levels of apoptosis in CEM cells. However, doxorubicin-induced apoptosis was increased >2-fold when exogenous RANKL was added. Therefore, RANKL is necessary but not sufficient to account for early doxorubicin-induced apoptosis in CEM cells. This finding suggests improved chemotherapeutic efficiency of the anthracyclin against susceptible malignant cells in the presence with RANKL.

KW - Antibiotics, Antineoplastic

KW - Apoptosis

KW - Carrier Proteins

KW - Cell Line

KW - Cytochrome c Group

KW - Doxorubicin

KW - Drug Synergism

KW - Humans

KW - Membrane Glycoproteins

KW - Mitochondria

KW - NF-kappa B

KW - RANK Ligand

KW - Receptor Activator of Nuclear Factor-kappa B

KW - Staurosporine

KW - T-Lymphocytes

KW - Tumor Necrosis Factor-alpha

M3 - SCORING: Journal article

C2 - 12702561

VL - 63

SP - 1772

EP - 1775

JO - CANCER RES

JF - CANCER RES

SN - 0008-5472

IS - 8

ER -